PD-L1 VHH Antibody

PD-L1，又被稱作 CD274 或是 B7H1，它是類型 I 的穿膜蛋白，被認為能夠通過與 PD1 受體的結合來抑制免疫反應，這會抑制 T 細胞的活化、增殖和細胞因子的產出。它擁有類似 V 型與 C 型的免疫球蛋白結構。PD-L1 的表現受多種細胞因子如 TNF-α 或 LPS 調節（ISSN: 1848-7718）。在特定癌症中，如腎癌或結腸癌，PD-L1 表達的增強與不好的預後有關。PD-L1 VHH Antibody 是一種基於 VHH 抗體的重組單克隆抗體，專門用於識別 PD-L1 蛋白，並因其高度的組織穿透力、結構穩定性和重組可塑性而被廣泛應用。

Official Name: Anti-PD-L1 VHH Antibody
Host: Alpaca
Clonality: Recombinant
Conjugation: Un-conjugated; with a 6xHis tag at its C-terminal
Application: ELISA, WB, IHC, IF, FACS
Reactivity: Human, Monkey
Affinity Constant: KD of 0.363 nM by Biacore T200
Formulation: 25 mM TAPS pH8.5, 500 mM NaCl, 5 mM EDTA, 0.1 % Proclin 300 Solution.
Storage: 4℃. Do not freeze.
Description: PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and Clike immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis.

立即詢價